Methotrexate and Cyclosporine in Treatment of Early Rheumatoid Arthritis
Rheumatoid ArthritisTo investigate whether cyclosporine, added to methotrexate and steroid, increases the possibility of inflammatory management early in the disease; furthermore to investigate the possible steroid-sparing effect of cyclosporine in patients with recently diagnosed rheumatoid arthritis.
Phase III Comparative Study(Open-Label) of MRA for Rheumatoid Arthritis(RA)
Rheumatoid ArthritisTo evaluate clinical efficacy and tolerability of MRA, patients with RA are randomized to receive either MRA or conventional DMARDs.
Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)
Systemic Juvenile Idiopathic ArthritisThis is a double-blind, Phase III study to evaluate the efficacy, safety and PK of MRA in patients with sJIA.
Study of MRA in Patients With Rheumatoid Arthritis (RA)
Rheumatoid ArthritisThis is an open-label, extension, Phase II study to evaluate the long-term safety and efficacy of MRA in Patients with RA who were participated in Study MRA009JP.
SPRiNG: SCIO-469 Patients With Rheumatoid Arthritis Not Receiving Methotrexate
ArthritisRheumatoidThe primary objective of this study is to determine the efficacy of oral SCIO-469 in patients with rheumatoid arthritis who are not receiving liver damaging (hepatotoxic) disease-modifying anti-rheumatic drugs (DMARDs).
Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk...
OsteoarthritisArthritis1 moreTo determine whether celecoxib is superior to combined therapy with diclofenac and omeprazole in the incidence of clinically significant upper and/or lower gastrointestinal (GI) events in high GI risk subjects with osteoarthritis and/or rheumatoid arthritis.
Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active...
Rheumatoid ArthritisTo compare, as a preliminary analysis, the effects of MEDI-522 versus placebo at 6 months on disease activity (ACR20) and progression of structural joint damage.
A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage...
Rheumatoid ArthritisThis 3 arm study will compare the safety and efficacy, with respect to a reduction in signs and symptoms and prevention of joint damage, of tocilizumab versus placebo, both in combination with methotrexate (MTX) in patients with moderate to severe active rheumatoid arthritis. Patients will be randomized to receive tocilizumab 4 mg/kg IV, tocilizumab 8 mg/kg IV or placebo IV, every 4 weeks. All patients will also receive methotrexate, 10-25 mg/week. The anticipated time on study treatment is 1-2 years and the target sample size is 500+ individuals. After completion of the 2 year study participants could participate in the optional 3 year open label extension phase (year 3 to 5).
A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With...
Rheumatoid ArthritisThis 3 arm study will compare the safety and efficacy, with regard to reduction of signs and symptoms, of tocilizumab versus placebo, both in combination with methotrexate (MTX). in patients with moderate to severe active rheumatoid arthritis (RA) who currently have an inadequate response to MTX. Patients wil be randomized to receive tocilizumab 4mg/kg iv, tocilizumab 8mg/mg iv, or placebo iv, every 4 weeks; all patients will also receive methotrexate 10-25mg weekly. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.
Safety, Efficacy and Pharmacokinetics of an Antibody for Psoriatic Arthritis
Psoriatic ArthritisThe purpose of this study is to determine whether a humanized monoclonal antibody (efalizumab) is safe and effective in the treatment of psoriatic arthritis (PsA)